Agnico Eagle Mines earnings beat by $0.19, revenue topped estimates
LONDON - Futura Medical (TASE:BLWV) plc (AIM:FUM), a consumer healthcare company known for developing sexual health products like Eroxon, has announced that its Annual General Meeting (AGM) will be held on Thursday, June 19, 2025. The meeting is set to take place at the offices of Panmure Liberum in London, as per the company’s recent statement.
Shareholders intending to attend the AGM are required to register by 10:00 am on June 16, 2025. Those unable to attend can cast their proxy votes online, use the CREST electronic proxy appointment service, or for institutional investors, the Proxymity platform. Proxy votes must be logged by 10:00 am on June 17, 2025. For those not present, the company will provide arrangements to listen to the proceedings remotely, although remote listeners will not have the opportunity to vote or interact during the meeting.
In addition, the company’s annual report for the year ending December 31, 2024, is now available on Futura Medical’s website. This report includes comprehensive accounts and the Notice of AGM, accessible to shareholders in line with the Companies Act 2006.
Futura Medical is recognized for its focus on research, development, and commercialization of topical gel formulations, primarily in the sexual health sector. Eroxon, the company’s flagship product for treating Erectile Dysfunction (ED), is the only topical gel treatment for ED available over the counter, with a quick action time of ten minutes. The product has received industry awards and holds distribution partnerships with major markets, including Haleon in the US and Cooper Consumer Health in Europe.
The company’s press release statement provides all the details regarding the upcoming AGM and the availability of the annual report. Shareholders and interested parties are encouraged to review the documents provided for complete information on the company’s performance and future plans.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.